As part of our heritage, in Australia CSL Seqirus plays a unique public health role, continuing a long legacy as the manufacturer and sole supplier of a range of products made for the Australian Government in the National Interest, including snake and spiderantivenoms and Q fever vaccine. ...
Seqirus, an influenza vaccine maker, is building a new cell-based influenza vaccine manufacturing facility in Melbourne, Australia. The facility will be a significant addition to the company’s global manufacturing and supply chain for the influenza vaccine, including the facilities in Holly Springs, ...
“We are excited to partner with CSL Seqirus to provide physicians and patients with additional options to treat high LDL-C cholesterol and reduce the risk of cardiovascular disease in Australia and New Zealand,” said Sheldo...
Seqirus, a subsidiary of Australia-based biotechnology firm CSL, has received the US Food and Drug Administration (FDA) approval for Audenz to protect against influenza A (H5N1) in case of a pandemic. Pandemic influenzais a contagious, airborne respiratory disease that affects all age groups, as...
(China, India, Japan, Singapore, Australia, New Zealand, Rest of APAC) Middle East & Africa (Turkey, Saudi Arabia, Iran, UAE, Africa, Rest of MEA) South America (Brazil, Argentina, Rest of SA) Market Players & Competitor Analysis: The report covers the key players of the industry ...
Seqirus is an attractive partner being a large local pharmaceutical company in Australia with a prominent track record in neurology. Australia and New Zealand are markets with resilient economies, substantial disease prevalence and established Parkinson’s ...
9 Seqirus recently announced plans to build a new, world-class cell-based manufacturing facility in Australia, which will be the only cell-based influenza vaccine manufacturing facility in the Southern Hemisphere.10 About the Studies Collectively these s...
facility is part of Seqirus' global manufacturing and supply network supporting seasonal influenza vaccine production and pandemic preparedness, including sites in Liverpool, UK, Parkville, Australia, as well as a new state-of-the-art facility currently under construction in Tullamarine,...
· Access to pre-pandemic vaccines using either cell- or egg-based manufacturing technologies from Seqirus' global network of production facilities, including Holly Springs, North Carolina; Liverpool, United Kingdom; and Parkville, Australia. In a pande...
Forward-Looking Statements This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding marketing strategy and commercialization plans, current and planned operational expenses, futur...